Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Articles|May 18, 2015
- Genitourinary (Issue 2)
- Issue 2
AR-V7 as a Biomarker in CRPC
Author(s)Emmanuel S. Antonarakis, MBBCh
Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).
Advertisement
Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).
<<<
Articles in this issue
over 11 years ago
Use of ARN-509 in Prostate Cancerover 11 years ago
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPCover 11 years ago
Study Illuminates Role of AR-V7 in Carcinogenesisover 11 years ago
PSA Screening Drops 50% Following USPSTF Recommendationover 11 years ago
Urine-Based Diagnostic Effectively Identifies Prostate Cancerover 11 years ago
Trends in PSA Utilization in Primary Care PhysiciansAdvertisement
Related to this article
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5